Melatonin Agb

Melatonin, the active ingredient in Melatonin Agb, is a melatonin receptor agonist presented as an oral formulation for oral use. It is used to treat insomnia and circadian rhythm sleep disorders in adults and, where appropriate, in pediatric patients.

GNH USA supplies Melatonin Agb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Melatonin Agb acts on the melatonin signaling pathway to help regulate sleep‑wake cycles. - Insomnia: improves sleep onset and reduces nighttime awakenings. - Circadian rhythm sleep disorder: aligns the internal clock with the external light‑dark cycle. - Shift work disorder: facilitates adaptation to irregular work schedules.

Melatonin Agb may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness: transient sensation of light‑headedness. - Daytime sleepiness: feeling unusually drowsy during waking hours. - Nausea: mild gastrointestinal discomfort. - Mild abdominal cramps: occasional stomach upset.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Severe depression: worsening mood or suicidal thoughts. - Hallucinations: visual or auditory disturbances. - Abnormal heart rhythm: palpitations or arrhythmia. - Severe hypotension: marked drop in blood pressure.

When considering Melatonin Agb, several safety measures should be observed. - Medical supervision: use only under guidance of a qualified health professional. - Hypersensitivity: avoid if known allergy to melatonin or excipients. - Hepatic impairment: exercise caution in patients with liver dysfunction. - Pediatric use: limit to ages and doses prescribed by a clinician. - Concomitant sedatives: monitor for additive sleep‑inducing effects. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Melatonin Agb can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Central nervous system depressants: may enhance sedative effects. - Anticoagulants (e.g., warfarin): potential increase in bleeding risk. - Immunosuppressants (e.g., cyclosporine): may reduce melatonin metabolism.

Moderate Interactions (Monitor Closely): - Caffeine: may diminish melatonin’s sleep‑promoting action. - Alcohol: can increase sedation and impair coordination. - Oral contraceptives: may elevate plasma melatonin levels. - Antihypertensives: possible additive blood‑pressure lowering effect. - Antiepileptic drugs: may alter melatonin clearance.